228 Results for "

LDL

" in MedChemExpress (MCE) Product Catalog:
Products (228)

228 Results for "LDL" in MCE Product Catalog:

Referencia número: HY-101354
No. CAS: 2133832-83-2
Pureza:  98.76%
Synonyms: PF-00932239
Target:  

PCSK9 Ras MEK ERK NF-κB LDLR

R-IMPP (PF-00932239) is a PCSK9 translation inhibitor and a selective 80S ribosome binder. R-IMPP inhibits the KRAS/MEK/ERK signaling cascade. R-IMPP reduces LPS-induced nuclear translocation of NFkB P65. R-IMPP increases LDL-R levels in cells, promotes LDL-C uptake, and does not alter the secretion of transferrin or albumin. R-IMPP inhibits the growth of colorectal cancer (CRC) cells, organoids and xenografts carrying APC/KRAS mutations, as well as the number and burden of spontaneous mouse tumors. R-IMPP can be used in research related to colorectal cancer with APC/KRAS mutations, hepatic ischemia-reperfusion injury and hypercholesterolemia .
loading...
    loading...
Referencia número: HY-N0859
No. CAS: 69363-14-0
Synonyms: Schizanhenol; Gomisin-K3
Schisanhenol (Schizanhenol), a lignan, is an orally active antioxidant. Schisanhenol reduces AChE activity, increases SIRT1 and PGC-1α expression, and decreases phosphorylated Tau (Ser 396) levels. Schisanhenol increases SOD and glutathione peroxidase activity, decreases malondialdehyde (MDA) content, and inhibits UGT2B7 activitY. Schisanhenol attenuates ox-LDL-induced apoptosis, intracellular reactive oxygen species generation, and cytotoxicity in endothelial cells. Schisanhenol inhibits LDL oxidation, brain mitochondrial and membrane peroxidative damage, and brain mitochondrial swelling and disintegration. Schisanhenol can be used for the research of Alzheimer’s disease, atherosclerosis, brain ischemia, and age-related brain deterioration .
loading...
    loading...
Referencia número: HY-P99793
No. CAS: 1314241-10-5
Synonyms: MLDL1278A

Target:  

LDLR

Áreas de investigación:  

Inflammation/Immunology

Orticumab (MLDL1278A) is an antibody targeting to oxidized or malondialdehyde-modified lipoprotein (LDL). Orticumab specifically inhibits oxidized low-density lipoproteins (oxLDL). Orticumab involves in modulation of autoimmune responses against oxLDL, improves atherosclerosis in animal model. Orticumab also can be used for research of psoriasis improvement .
loading...
    loading...
Referencia número: HY-10473
No. CAS: 355129-15-6
Pureza:  99.77%
Synonyms: KB2115
Áreas de investigación:  

Metabolic Disease Endocrinology

Eprotirome (KB2115) is a liver-selective thyroid hormone receptor (TR) agonist. KB2115 has modestly higher affinity for TRβ than for TRα. Eprotirome reduces low-density lipoprotein (LDL) cholesterol concentrations. Eprotirome can be used for dyslipidemias and obesity research .
loading...
    loading...
Referencia número: HY-125544
No. CAS: 152755-31-2
Pureza:  ≥98.0%
Synonyms: Agisterol
Target:  

LDLR

Áreas de investigación:  

Metabolic Disease

LY 295427 is a LDL receptor modulator and a hypocholesterolemic agent. LY 295427 derepresses the transcription of the LDLR (LDL Receptor). LY 295427 can be used for hypercholesterolemia research .
loading...
    loading...
Referencia número: HY-W010697
No. CAS: 604-33-1
Cholesteryl linoleate is a cholesteryl ester with antibacterial activity that is present in low-density lipoprotein (LDL) particles, human nasal fluid, and respiratory epithelial secretions. Cholesteryl linoleate is oxidized by 12/15-lipoxygenase in macrophages and participates in selective uptake and efflux via LDL receptor-related protein. Cholesteryl linoleate does not induce endothelial adhesion molecule expression, nor does it induce monocyte binding to endothelial cells. Cholesteryl linoleate liposomal formulations inhibit the growth of multiple bacteria at physiological nasal fluid concentrations and act synergistically with antimicrobial peptides. Cholesteryl linoleate is useful for research related to atherosclerosis and bacterial infections .
loading...
    loading...
Referencia número: HY-158827A
Target:  

PCSK9

Áreas de investigación:  

Metabolic Disease

AZD8233 sodium, a liver-targeting antisense oligonucleotide (ASO), inhibits subtilisin/kexin type 9 (PCSK9) protein synthesis. AZD8233 sodium increases the available LDL receptors by reducing PCSK9 levels, thereby clearing LDL from the blood and decreasing LDL-C levels.
loading...
    loading...
Referencia número: HY-101529
No. CAS: 75689-93-9
Pureza:  99.03%
Synonyms: HOE-402free base
Target:  

LDLR

Áreas de investigación:  

Cardiovascular Disease

Imanixil (HOE-402 free base) is an orally active LDL receptor (LDLR) inducer. Imanixil can reduce cholesterol levels by inhibiting VLDL-lipid production. Imanixil can delay atherosclerosis profession. Imanixil can be used for the research of cardiovascular disease, such as atherosclerosis .
loading...
    loading...
Referencia número: HY-126726
No. CAS: 439904-33-3
Pureza:  99.00%
Áreas de investigación:  

Others

Oxidized low-density lipoprotein (oxLDL) particles contain low molecular weight species that are cytotoxic and proatherogenic. Many of these species were recently isolated and purified from oxLDL and identified as phosphatidylcholine species containing fragmented oxidized short-chain fatty acid residues at the sn-2 position. 1-(Palmitoyl)-2-(5-keto-6-octene-dioyl)phosphatidylcholine or KOdiA-PC is one of the most potent CD36 ligands of the oxLDL species. KOdiA-PC confers CD36 scavenger receptor binding affinity to LDL at a frequency of only 2 to 3 KOdiA-PC molecules/LDL particle and may be one of the more important structural determinants of oxLDL.
loading...
    loading...
Referencia número: HY-149120
No. CAS: 2913151-46-7
Pureza:  98.65%
Target:  

Phospholipase

Áreas de investigación:  

Cardiovascular Disease Inflammation/Immunology

ASM-IN-1 is a potent and orally active acid sphingomyelinase (ASM) inhibitor with an IC50 value of 1.5 µM. ASM-IN-1 reduces lipid plaques in the aortic arch and aorta and reduces plasma ceramide concentration and Ox-LDL levels. ASM-IN-1 shows antiatherosclerotic and anti-inflammatory activity .
loading...
    loading...
Referencia número: HY-P99552
No. CAS: 2225109-03-3
Synonyms: IBI-306

Target:  

PCSK9

Áreas de investigación:  

Cardiovascular Disease

Tafolecimab (IBI-306) is a human lgG2 monoclonal antibody that specifically binds PCSK-9 and reduces LDL-C levels by inhibiting PCSK-9-mediated endocytosis of the LDL receptor, which in turn enhances clearance of LDL-C and leads to a reduction in LDL-C levels. Tafolecimab may be used in studies of hypercholesterolaemia .
loading...
    loading...
Referencia número: HY-N0339R
No. CAS: 530-57-4
Syringic acid (Standard) is the analytical standard of Syringic acid. This product is intended for research and analytical applications. Syringic acid is correlated with high antioxidant activity and inhibition of LDL oxidation.
loading...
    loading...
Referencia número: HY-B0388R
No. CAS: 23288-49-5
Synonyms: DH-581 (Standard)
Áreas de investigación:  

Metabolic Disease

Probucol (Standard) is the analytical standard of Probucol. This product is intended for research and analytical applications. Probucol (DH-581) is an anti-hyperlipidemic agent by lowering the level of cholesterol in the bloodstream by increasing the rate of LDL catabolism.
loading...
    loading...
Referencia número: HY-148758
No. CAS: 2244129-23-3
Pureza:  98.00%
Target:  

PCSK9

Áreas de investigación:  

Cardiovascular Disease Metabolic Disease

PCSK9-IN-13(compound 3f) is a potent PCSK9 inhibitor, which can antagonize low-density lipoprotein (LDL) receptor binding by binding to PCSK9, with an IC50 of 537 nM .
loading...
    loading...
Referencia número: HY-P99626
No. CAS: 1643672-70-1
Synonyms: LY 3015014

Target:  

PCSK9

Áreas de investigación:  

Metabolic Disease

Frovocimab (LY 3015014) is a humanized IgG4 monoclonal antibody (mAb) that neutralizes PCSK9. Frovocimab inhibits PCSK9 binding to LDL receptor (LDLR) while permitting the normal proteolytic cleavage of the bound intact PCSK9 .
loading...
    loading...
Referencia número: HY-157434
No. CAS: 2115700-96-2
Pureza:  99.57%
Target:  

PCSK9

Áreas de investigación:  

Cardiovascular Disease

PCSK9-IN-23 (compound 5C) is a potent PCSK9 inhibitor. PCSK9-IN-23 blocks PCSK9 secretion from HepG2 cells, significantly increases LDL receptor (LDLR) expression .
loading...
    loading...
Referencia número: HY-P11071
Target:  

PCSK9 LDLR

Áreas de investigación:  

Cardiovascular Disease

PCSK9 Inhibitor, EGF-A is a PCSK9 inhibitor with LDLR degradation inhibitory activity and LDLR recycling promoting activity. PCSK9 Inhibitor, EGF-A is a synthetic peptide consisting of 42 amino acid residues, which contains the calcium-binding site of the epidermal growth factor A domain (EGF-A). PCSK9 Inhibitor, EGF-A reduces plasma LDL cholesterol levels by maintaining hepatic LDLR levels and enhancing the clearance capacity of circulating LDL. PCSK9 Inhibitor, EGF-A can be used in research related to hypercholesterolemia, premature atherosclerosis, coronary heart disease and familial hypercholesterolemia .
loading...
    loading...
Referencia número: HY-120651
No. CAS: 778624-05-8
Pureza:  ≥99.0%
Target:  

LDLR

Áreas de investigación:  

Metabolic Disease

LDL-IN-2 (compound 3) is an antioxidant against copper mediated low-density lipoproteins (LDL) oxidation .
loading...
    loading...
Referencia número: HY-N3596
No. CAS: 84575-10-0
Synonyms: Aquillochin
Cleomiscosin C (Aquillochin) can be isolated from Aquilaria agallocha. Cleomiscosin C has antioxidant activity. Cleomiscosin C inhibits LDL oxidation and free radicals generation .
loading...
    loading...
Referencia número: HY-148626
Target:  

PCSK9

Áreas de investigación:  

Metabolic Disease

CVI-LM001 is an inhibitor PCSK 9. CVI-LM001 inhibits the interaction of PCSK9 with low-density lipoprotein receptor (LDLR), regulates the level of low-density lipoprotein cholesterol (LDL-C) in the blood, and exhibits lipid-lowering efficacy .
loading...
    loading...